Precision psychiatry, also termed personalized psychiatry or precision medicine in psychiatry, epitomizes a contemporary approach to psychiatric treatment, tailoring interventions to individual patients based on their unique characteristics, including genetic makeup, neurobiological markers, and environmental influences. Departing from the one-size-fits-all approach of traditional psychiatric treatments, precision psychiatry harnesses advancements in genetics, neuroimaging, and data analytics to identify biomarkers associated with psychiatric disorders and treatment response. Genetic variations influencing medication response or adverse effects can inform clinicians in optimizing medication selection and dosages, maximizing efficacy, and minimizing side effects for each patient. Neuroimaging techniques such as fMRI and EEG offer valuable insights into brain function and connectivity, aiding in identifying neural patterns linked to specific psychiatric symptoms or treatment outcomes. Moreover, precision psychiatry emphasizes considering environmental factors like stress, trauma, and lifestyle habits in understanding psychiatric disorders and tailoring treatment plans holistically. By adopting this comprehensive approach, clinicians can address underlying contributors to mental illness and customize interventions accordingly. In essence, precision psychiatry signifies a paradigm shift in psychiatric practice, toward personalized and efficacious treatments for individuals with mental health conditions. By leveraging genetics, neurobiology, and environmental factors, clinicians can deliver targeted interventions that enhance outcomes and overall well-being for patients.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States